Following STZ treatment (200 mg/kg, i.p.), 88.75% (n=80) of the MMP-9-/- mice developed hyperglycemia (vs. 86%, n=150 wild-type, WT) (Fig. 3A) and 56.25% (n=80) of the MMP-9-/- mice developed mechanical allodynia (vs. 60.67%, n=150 WT) (Fig. 3A). This evidence concerns the gene MMP9 and Hyperglycemia.